Charm Therapeutics
PrivateLast Round
Series B
Sep 2, 2025
Total Funding Raised
$130M
Company Overview
Charm Therapeutics operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series B round in September 2025.
Charm Therapeutics is a biotechnology company that utilizes a proprietary AI-driven drug discovery platform, DragonFold, to develop transformative medicines for patients with challenging diseases such as cancer.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Charm Therapeutics Comparables
Compare Charm Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genesis Therapeutics | 87% | |
| Iambic Therapeutics | 85% | |
| Peptone | 83% |
For institutional investors. Book with your work email.
Charm Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 2, 2025 | ||||
| VC Round | Apr 14, 2023 | ||||
| Series A | Jun 9, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Charm Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Braavos Investment Advisers | Series A |
| New Enterprise Associates | Series B |
| Khosla Ventures | Series A, Series B |
| Grep VC | Series A |
| F-Prime Capital | Series B, Series A |
| OrbiMed | Series B, Series A |
| General Catalyst | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 8, 2025
Dr. Erkut Bahceci appointed as the new Chief Medical Officer.
- Sep 2, 2025
$80M round completed.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 11, 2026
CHARM Therapeutics Ltd plans to present preclinical data on CHM-029 and its Phase I/II trial design at the 8th ASH Annual Meeting in Louisiana in Dec '26.
- attends_eventNov 11, 2026
CHARM Therapeutics Ltd has two posters on preclinical CHM-029 data and its ongoing Phase I/II clinical trial design scheduled for presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition in Louisiana from Dec 12th to 15th '26.
For institutional investors. Book with your work email.
Charm Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Charm Therapeutics's valuation, stock price, and market status.
Is Charm Therapeutics a public or private company?
Charm Therapeutics is a private company.
What is the current stock price of Charm Therapeutics?
Charm Therapeutics is a private company, so its shares have no public market price. Caplight tracks Charm Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Charm Therapeutics worth (valuation)?
Valuation information for Charm Therapeutics is not publicly available.
Can I buy Charm Therapeutics stock?
Charm Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Charm Therapeutics's last funding round?
Charm Therapeutics's most recent funding round was Series B on September 2, 2025.
Who are the main investors in Charm Therapeutics?
Key investors in Charm Therapeutics include New Enterprise Associates, F-Prime Capital, OrbiMed, NVentures, F-Prime Capital.
Will Charm Therapeutics IPO soon?
No public IPO plans have been announced for Charm Therapeutics.
How can I track Charm Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Charm Therapeutics's shares on secondary markets.